Dementia and Alzheimer Disease

Epilepsy

Headache and Migraine

Movement Disorders

Multiple Sclerosis

Neuromuscular

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

eNewsletter

Print Subscription

Articles

During a 12-week treatment period, investigators observed greater reduction in change from baseline in UPDRS score for those on electroacupuncture than just on PD medication alone.

Electroacupuncture Provides Additive Benefits for Motor Function and Bowel Movements in Parkinson Disease

Videos

The assistant professor of neurology at Yale School of Medicine spoke about the importance of the relaunch of the patient registry for research in myasthenia gravis. [WATCH TIME: 3 minutes]  

Significance of Relaunched Patient Registry for Myasthenia Gravis Research: Richard Nowark, MD, MS

The trial was originally placed on hold because of reported cases of drug-induced liver injury in patients who received the study drug, potentially caused by a preexisting factors related to hepatic dysfunction.

Sanofi Discontinues Phase 3 Study of Tolebrutinib in Myasthenia Gravis

Factoring in the complex nature of the disease, a group of experts provided perspectives on how clinically meaningful benefit should be viewed, stressing the importance of early intervention.

Alzheimer’s Association Panel Offers Considerations for New Definition of Meaningful Change in Drug Trials

The chief training and education officer at the Parkinson’s Foundation detailed the challenges in disseminating educational materials to the clinical community that could have impacts on Parkinson disease care. [WATCH TIME: 5 minutes]

Reaching a Broader Community of Health Care Professionals to Improve PD Care: Eli Pollard

The chief training and education officer at the Parkinson’s Foundation discussed the importance of educating healthcare professionals on different specialists that play a role in Parkinson disease management. [WATCH TIME: 2 minutes]

Educating and Diversifying Clinicians to Help Overcome Gaps in Parkinson Disease Management: Eli Pollard

The director of the Montefiore Einstein Center for the Aging Brain provided insight on expanding the use of the 5-Cog tool, and whether it can be used for other conditions like HIV or COVID-19. [WATCH TIME: 3 minutes]

Adopting the 5-Cog Assessment Nationally, Other Cognitive Conditions: Joe Verghese, MBBS, MS

The chief training and education officer at the Parkinson’s Foundation provided perspective on the vast types of medical professionals who can learn from the organization’s new education series. [WATCH TIME: 4 minutes]

Educating and Easing Interdisciplinary Care Teams to Treat Parkinson Disease: Eli Pollard

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

Spotlight

NMOSD

Narcolepsy

Parkinson Disease

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

 Peer Exchange video series features panels of expert physicians engaging in in-depth discussions about practice-changing treatments, challenges in care, and the future paradigm of management for neurologic diseases.

Peer Exchange

1rem

Management of Cardiac Amyloidosis 

Cardiac Amyloidosis Diagnostic Workup

Hypertrophic Cardiomyopathy Historical Prognosis

AL and ATTR Diagnosis: Echo and Noncardiac Biopsy

When Are Heart Biopsies Warranted?

Technetium Pyrophosphate Scan Benefits

Monoclonal Protein Testing and Wild-Type ATTR

Technetium Pyrophosphate Scan Prior to TAVR

AL and ATTR Survival Metrics

Poor Toleration: AL and ATTR Treatment Modification

Cardioversion and Atrial Fibrillation Ablation 

Cardiac Amyloidosis: Pacemakers and Defibrillators

Therapy Selection for Congestive Heart Failure

Available ATTR Selective Stabilizers

Cardiomyopathy Management: NSAID Options

TTR Gene Silencers as Cardiomyopathy Treatment

Developing Agents for Cardiac Amyloidosis Management